RGS9 Gene and Its Link to Methamphetamine Use Disorder and Schizophrenia
Author Information
Author(s): Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Ujike H
Primary Institution: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hypothesis
Is there an association between the RGS9 gene and susceptibility to schizophrenia and methamphetamine use disorder?
Conclusion
The RGS9 gene is unlikely to play a major role in schizophrenia and methamphetamine dependence in the Japanese population.
Supporting Evidence
- The study included 487 patients with schizophrenia and 220 patients with methamphetamine use disorder.
- Genotyping was performed on two polymorphisms of the RGS9 gene.
- No significant differences were found in genotypic or allelic distributions between patients and controls.
- A significant association was found in allelic distribution with the age at first consumption of methamphetamine.
Takeaway
Scientists studied a gene called RGS9 to see if it affects people with schizophrenia or those who use methamphetamine, but they found it doesn't seem to matter much.
Methodology
The study involved genotyping two polymorphisms of the RGS9 gene in patients with schizophrenia and methamphetamine use disorder compared to healthy controls.
Limitations
The significance of the findings regarding age at first consumption was marginal and requires further confirmation.
Participant Demographics
The study included 220 patients with methamphetamine dependence and 487 patients with schizophrenia, all of whom were Japanese.
Statistical Information
P-Value
0.047
Statistical Significance
p=0.047
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website